We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+28.17%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$5.72B
AUM Growth
+$1.22B
Cap. Flow
+$567M
Cap. Flow %
9.91%
Top 10 Hldgs %
84.78%
Holding
119
New
24
Increased
23
Reduced
25
Closed
11

Top Buys

Rank Stock Value
1
GS icon
Goldman Sachs
GS
+$22.2M
2
MDCO
Medicines Co
MDCO
+$11.1M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$10.9M
4
INCY icon
Incyte
INCY
+$9.54M
5
NKTR icon
Nektar Therapeutics
NKTR
+$7.71M

Top Sells

Rank Stock Value
1
BABA icon
Alibaba
BABA
+$27M
2
ATH
Athene Holding Ltd. Class A Common Shares
ATH
+$12.8M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.82M
4
ZTO icon
ZTO Express
ZTO
+$6.21M
5
SAGE
Sage Therapeutics
SAGE
+$6.14M

Sector Composition

Rank Sector Weight
1 Consumer Staples 34.97%
2 Healthcare 25.04%
3 Consumer Discretionary 17.19%
4 Financials 0.66%
5 Industrials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BUFF
1
DELISTED
Blue Buffalo Pet Products, Inc
BUFF
$1.99B 34.85%
87,460,875
– –
WW
2
DELISTED
WW International
WW
$984M 17.19%
29,443,300
– –
LXRX icon
3
Lexicon Pharmaceuticals
LXRX
$1.04B
$946M 16.53%
57,517,977
– –
GS icon
4
CALL
Goldman Sachs
GS
$294B
$322M 5.62%
1,450,000
+1,150,000
+383% +$256M
BAC icon
5
CALL
Bank of America
BAC
$433B
$205M 3.58%
8,450,000
+4,950,000
+141% +$115M
MET icon
6
CALL
MetLife
MET
$62.4B
$137M 2.4%
2,805,000
+841,500
+43% +$39M
GILD icon
7
CALL
Gilead Sciences
GILD
$166B
$88.5M 1.55%
1,250,000
+750,000
+150% +$49.9M
MSFT icon
8
CALL
Microsoft
MSFT
$2.95T
$68.9M 1.2%
+1,000,000
New +$68.6M
BMY icon
9
CALL
Bristol-Myers Squibb
BMY
$129B
$55.7M 0.97%
1,000,000
– –
INCY icon
10
Incyte
INCY
$25.6B
$50.4M 0.88%
400,000
+75,000
+23% +$9.54M
ABBV icon
11
CALL
AbbVie
ABBV
$469B
$36.3M 0.63%
+500,000
New +$33.6M
WFC icon
12
CALL
Wells Fargo
WFC
$257B
$36M 0.63%
650,000
-150,000
-19% -$8.04M
AGIO icon
13
Agios Pharmaceuticals
AGIO
$2.1B
$36M 0.63%
700,000
-50,000
-7% -$2.56M
C icon
14
CALL
Citigroup
C
$215B
$33.4M 0.58%
500,000
– –
TSRO
15
CALL
DELISTED
TESARO, Inc.
TSRO
$32.9M 0.57%
235,000
+168,600
+254% +$24.4M
IBM icon
16
CALL
IBM
IBM
$216B
$30.8M 0.54%
209,200
+104,600
+100% +$15.8M
NKTR icon
17
Nektar Therapeutics
NKTR
$2.35B
$27.4M 0.48%
93,333
+26,666
+40% +$7.71M
BLUE
18
DELISTED
bluebird bio
BLUE
$26.3M 0.46%
19,300
– –
NBIX icon
19
Neurocrine Biosciences
NBIX
$18.3B
$25.3M 0.44%
550,000
+225,000
+69% +$10.9M
INCY icon
20
CALL
Incyte
INCY
$25.6B
$25.2M 0.44%
+200,000
New +$25.4M
BMRN icon
21
BioMarin Pharmaceuticals
BMRN
$11.9B
$22.7M 0.4%
250,000
-75,000
-23% -$6.82M
MS icon
22
CALL
Morgan Stanley
MS
$324B
$22.3M 0.39%
+500,000
New +$21.6M
GS icon
23
Goldman Sachs
GS
$294B
$22.2M 0.39%
+100,000
New +$22.2M
ALNY icon
24
Alnylam Pharmaceuticals
ALNY
$38.2B
$21.9M 0.38%
275,000
-25,000
-8% -$1.6M
XLRN
25
DELISTED
Acceleron Pharma
XLRN
$21.3M 0.37%
700,000
-50,000
-7% -$1.45M
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2017 Portfolio in Review

As of Q2 2017, Artal Group held 119 positions worth $5.72B, up 27% from $4.51B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Artal Group deployed $567M of net new capital in Q2 2017, opening 24 new positions and adding to 23 existing holdings. Its largest new stake was Goldman Sachs: 100,000 shares worth $22.2M.

By sector, the portfolio is most concentrated in Consumer Staples at 35% of assets, down from 45% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Athene Holding Ltd. Class A Common Shares, an estimated $12.8M trimmed.

  • Artal Group's largest Q2 2017 buy was Goldman Sachs: 100,000 shares worth $22.2M.
  • Artal Group added most to Medicines Co in Q2 2017, an estimated $11.1M increase.
  • Artal Group's biggest Q2 2017 reduction was Athene Holding Ltd. Class A Common Shares, cutting an estimated $12.8M.
  • Artal Group fully exited Alibaba in Q2 2017, selling an estimated $27M.
  • Artal Group's ten largest holdings make up 85% of its $5.72B portfolio in Q2 2017.
  • Artal Group opened 24 new positions and closed 11 in Q2 2017.
  • Artal Group's portfolio value rose 27% quarter-over-quarter to $5.72B.

Based on Artal Group's 13F filing for Q2 2017, filed 11 Aug 2017.